Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients

A Pilot Study, Prospective, Non-Randomized, Non-Blinded, Single-Center Study Evaluating the Response of Continuous Recombinant Antithrombin (ATryn) Infusion in Postcardiotomy ECMO Patients

The objective of this study will be to prospectively evaluate the response of a continuous infusion of recombinant human antithrombin concentrate (rhAT) (ATRYN®) to achieve and maintain the AT activity within a specified range in adult patients that require extracorporeal membrane oxygenation (ECMO) following cardiopulmonary bypass (CPB) and cardiac surgery.

Inclusion Criteria:

• Completed cardiac surgery with Cardiopulmonary Bypass and subsequently placed on venoarterial (VA) Extracorporeal Membrane Oxygenation (ECMO) support at any point during the ongoing hospitalization
• Serum Antithrombin < 60%.

Exclusion Criteria:

• Heart transplantation during ongoing hospitalization
• Excessive bleeding (300 ml/hr of chest tube drainage for 2 consecutive hours)
• Weight < 40 kg
• Allergy to goat products
• Anticoagulation with a direct thrombin inhibitor
• Religious exception to blood products
• Hypothermia (< 34°C)